PL96785B1 - Sposob wytwarzania nowych benzyloamin - Google Patents
Sposob wytwarzania nowych benzyloamin Download PDFInfo
- Publication number
- PL96785B1 PL96785B1 PL18143374A PL18143374A PL96785B1 PL 96785 B1 PL96785 B1 PL 96785B1 PL 18143374 A PL18143374 A PL 18143374A PL 18143374 A PL18143374 A PL 18143374A PL 96785 B1 PL96785 B1 PL 96785B1
- Authority
- PL
- Poland
- Prior art keywords
- general formula
- group
- hydrogen
- carbon atoms
- bromo
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 27
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000000460 chlorine Chemical group 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 150000003939 benzylamines Chemical class 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 3
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 125000002560 nitrile group Chemical group 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- ZOXVJCUXZNPIGB-UHFFFAOYSA-N 4-(1-methylpiperazin-2-yl)morpholine Chemical compound CN1CCNCC1N1CCOCC1 ZOXVJCUXZNPIGB-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- -1 morpholinocarbonylmethyl group Chemical group 0.000 claims 6
- 150000007522 mineralic acids Chemical class 0.000 claims 4
- CHRAJVQLWOMYQI-SCZZXKLOSA-N (1s,5r)-5,8,8-trimethyl-3-azabicyclo[3.2.1]octane Chemical group C1NC[C@H]2CC[C@]1(C)C2(C)C CHRAJVQLWOMYQI-SCZZXKLOSA-N 0.000 claims 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000767 anti-ulcer Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IMCWZTJQZQPAEW-UHFFFAOYSA-N C(CCC)C(C1=CC=CC=C1)N(C)C1CCCCC1 Chemical compound C(CCC)C(C1=CC=CC=C1)N(C)C1CCCCC1 IMCWZTJQZQPAEW-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- IIEWBAQJZGHTKE-UHFFFAOYSA-N n-[2-bromo-6-(diethylaminomethyl)-4-methylphenyl]acetamide Chemical compound CCN(CC)CC1=CC(C)=CC(Br)=C1NC(C)=O IIEWBAQJZGHTKE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- ZXWCKKSSCIFVBT-UHFFFAOYSA-N 1-(3-fluorophenyl)-n-methylmethanamine Chemical compound CNCC1=CC=CC(F)=C1 ZXWCKKSSCIFVBT-UHFFFAOYSA-N 0.000 description 1
- GQQHWOKJSYGYEF-UHFFFAOYSA-N 1-[4-amino-3-bromo-5-[[cyclohexyl(ethyl)amino]methyl]phenyl]ethanol Chemical compound C1CCCCC1N(CC)CC1=CC(C(C)O)=CC(Br)=C1N GQQHWOKJSYGYEF-UHFFFAOYSA-N 0.000 description 1
- FXWFZIRWWNPPOV-UHFFFAOYSA-N 2-aminobenzaldehyde Chemical class NC1=CC=CC=C1C=O FXWFZIRWWNPPOV-UHFFFAOYSA-N 0.000 description 1
- LGUWYDNFNMYQLI-UHFFFAOYSA-N 4-amino-3-bromo-5-(diethylaminomethyl)benzonitrile Chemical compound CCN(CC)CC1=CC(C#N)=CC(Br)=C1N LGUWYDNFNMYQLI-UHFFFAOYSA-N 0.000 description 1
- SNMVVJCMCJFRAU-UHFFFAOYSA-N 4-amino-3-bromo-5-formylbenzoic acid Chemical compound NC1=C(C=O)C=C(C=C1Br)C(=O)O SNMVVJCMCJFRAU-UHFFFAOYSA-N 0.000 description 1
- VKKBXHJUULMKQC-UHFFFAOYSA-N 4-bromo-2-[[cyclohexyl(ethyl)amino]methyl]-6-fluoroaniline Chemical compound C1CCCCC1N(CC)CC1=CC(Br)=CC(F)=C1N VKKBXHJUULMKQC-UHFFFAOYSA-N 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- NQFYIGMNLLHATJ-UHFFFAOYSA-N Cl.NC1=C(CN(C)C2CCCCC2)C=C(C=C1C)Br Chemical compound Cl.NC1=C(CN(C)C2CCCCC2)C=C(C=C1C)Br NQFYIGMNLLHATJ-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000006487 butyl benzyl group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- KRALOLGXHLZTCW-UHFFFAOYSA-L calcium;2-acetyloxybenzoate Chemical group [Ca+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O KRALOLGXHLZTCW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- NWVBFFUWZFPOHK-UHFFFAOYSA-N ethyl 3-bromo-4-(butanoylamino)-5-(diethylaminomethyl)benzoate Chemical compound CCCC(=O)NC1=C(Br)C=C(C(=O)OCC)C=C1CN(CC)CC NWVBFFUWZFPOHK-UHFFFAOYSA-N 0.000 description 1
- NSPDFNKTKFZSHA-UHFFFAOYSA-N ethyl 4-amino-3-bromo-5-(diethylaminomethyl)benzoate Chemical compound CCOC(=O)C1=CC(Br)=C(N)C(CN(CC)CC)=C1 NSPDFNKTKFZSHA-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- SXPICPMNLWIBOO-UHFFFAOYSA-N n,n-dimethyl-1-phenylpentan-1-amine Chemical compound CCCCC(N(C)C)C1=CC=CC=C1 SXPICPMNLWIBOO-UHFFFAOYSA-N 0.000 description 1
- DTZVRIVVGLLEPI-UHFFFAOYSA-N n-[4-bromo-2-methyl-6-(morpholin-4-ylmethyl)phenyl]acetamide Chemical compound CC(=O)NC1=C(C)C=C(Br)C=C1CN1CCOCC1 DTZVRIVVGLLEPI-UHFFFAOYSA-N 0.000 description 1
- LSZODIVUHOJJHS-UHFFFAOYSA-N n-[4-bromo-5-tert-butyl-2-(diethylaminomethyl)phenyl]acetamide Chemical compound CCN(CC)CC1=CC(Br)=C(C(C)(C)C)C=C1NC(C)=O LSZODIVUHOJJHS-UHFFFAOYSA-N 0.000 description 1
- VFZWCTYGZWDQGK-UHFFFAOYSA-N n-benzylhexan-1-amine Chemical compound CCCCCCNCC1=CC=CC=C1 VFZWCTYGZWDQGK-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19742405322 DE2405322A1 (de) | 1974-02-05 | 1974-02-05 | Neue verfahren zur herstellung von benzylaminen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL96785B1 true PL96785B1 (pl) | 1978-01-31 |
Family
ID=5906596
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18143274A PL94279B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143674A PL94232B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143174A PL96532B1 (pl) | 1974-02-05 | 1974-04-12 | Sposob wytwarzania nowych benzyloamin |
| PL18143774A PL94234B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143374A PL96785B1 (pl) | 1974-02-05 | 1974-04-12 | Sposob wytwarzania nowych benzyloamin |
| PL18143574A PL94231B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143474A PL95668B1 (pl) | 1974-02-05 | 1974-04-12 | Sposob wytwarzania nowych benzyloamin |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18143274A PL94279B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143674A PL94232B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143174A PL96532B1 (pl) | 1974-02-05 | 1974-04-12 | Sposob wytwarzania nowych benzyloamin |
| PL18143774A PL94234B1 (Direct) | 1974-02-05 | 1974-04-12 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18143574A PL94231B1 (Direct) | 1974-02-05 | 1974-04-12 | |
| PL18143474A PL95668B1 (pl) | 1974-02-05 | 1974-04-12 | Sposob wytwarzania nowych benzyloamin |
Country Status (5)
| Country | Link |
|---|---|
| CH (7) | CH609038A5 (Direct) |
| DE (1) | DE2405322A1 (Direct) |
| ES (1) | ES433900A1 (Direct) |
| PL (7) | PL94279B1 (Direct) |
| SU (7) | SU527134A3 (Direct) |
-
1974
- 1974-02-05 DE DE19742405322 patent/DE2405322A1/de active Pending
- 1974-04-09 CH CH529177A patent/CH609038A5/xx not_active IP Right Cessation
- 1974-04-09 CH CH529077A patent/CH609037A5/xx not_active IP Right Cessation
- 1974-04-09 CH CH529277A patent/CH609329A5/xx not_active IP Right Cessation
- 1974-04-09 CH CH529477A patent/CH592609A5/xx not_active IP Right Cessation
- 1974-04-09 CH CH528877A patent/CH609035A5/xx not_active IP Right Cessation
- 1974-04-09 CH CH528977A patent/CH609036A5/xx not_active IP Right Cessation
- 1974-04-12 PL PL18143274A patent/PL94279B1/pl unknown
- 1974-04-12 PL PL18143674A patent/PL94232B1/pl unknown
- 1974-04-12 PL PL18143174A patent/PL96532B1/pl unknown
- 1974-04-12 PL PL18143774A patent/PL94234B1/pl unknown
- 1974-04-12 PL PL18143374A patent/PL96785B1/pl unknown
- 1974-04-12 PL PL18143574A patent/PL94231B1/pl unknown
- 1974-04-12 PL PL18143474A patent/PL95668B1/pl unknown
-
1975
- 1975-01-17 ES ES433900A patent/ES433900A1/es not_active Expired
- 1975-01-30 SU SU2101060A patent/SU527134A3/ru active
- 1975-01-30 SU SU752101062A patent/SU640657A3/ru active
- 1975-01-30 SU SU2101063A patent/SU521838A3/ru active
- 1975-01-30 SU SU2101049A patent/SU520035A3/ru active
- 1975-01-30 SU SU7502101047A patent/SU575021A3/ru active
- 1975-01-30 SU SU2101058A patent/SU523634A3/ru active
- 1975-01-30 SU SU2101064A patent/SU528866A3/ru active
-
1977
- 1977-04-28 CH CH529377A patent/CH617662A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL94231B1 (Direct) | 1977-07-30 |
| SU520035A3 (ru) | 1976-06-30 |
| SU527134A3 (ru) | 1976-08-30 |
| PL94234B1 (Direct) | 1977-07-30 |
| CH609036A5 (en) | 1979-02-15 |
| DE2405322A1 (de) | 1975-09-04 |
| CH609038A5 (en) | 1979-02-15 |
| PL95668B1 (pl) | 1977-11-30 |
| CH609035A5 (en) | 1979-02-15 |
| PL94279B1 (Direct) | 1977-07-30 |
| SU575021A3 (ru) | 1977-09-30 |
| CH609329A5 (en) | 1979-02-28 |
| PL96532B1 (pl) | 1977-12-31 |
| SU528866A3 (ru) | 1976-09-15 |
| ES433900A1 (es) | 1976-12-01 |
| SU640657A3 (ru) | 1978-12-30 |
| CH609037A5 (en) | 1979-02-15 |
| CH617662A5 (en) | 1980-06-13 |
| PL94232B1 (Direct) | 1977-07-30 |
| CH592609A5 (Direct) | 1977-10-31 |
| SU521838A3 (ru) | 1976-07-15 |
| SU523634A3 (ru) | 1976-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI64159B (fi) | Foerfarande foer framstaellning av oralt effektiva antiallergiska 11-oxo-11-h-pyrido(2,1-b)-kinazoliner | |
| CS247073B2 (en) | Production method of 2-substituted 4-amino-6,7-dimethoxyghinolins | |
| NO166862B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,8-nafthyridinderivater og deres salter, solvater, hydrater og estere. | |
| JPS5874666A (ja) | アルカノイルアニリド酸 | |
| US5135931A (en) | Pyridinylpiperazine derivatives | |
| US4159341A (en) | Anti-allergic bis-phenylene compositions and methods of using same | |
| US4041032A (en) | Pyrazine derivatives | |
| US4691018A (en) | Pyridine derivatives and their use as anti-allergic agents | |
| US3954748A (en) | 3-Alkoxy-thianapthene-2-carboxamides | |
| CN108863892B (zh) | 一种含酰胺结构的没食子酸甲酯类似物及应用 | |
| JPS61109767A (ja) | オキシンドール抗炎症剤 | |
| PL96785B1 (pl) | Sposob wytwarzania nowych benzyloamin | |
| US3812136A (en) | Tri-substituted imidazoles | |
| US5059599A (en) | Derivatives of 1-phenyl 1,4-dihydro 3-amino 4-oxo pyridazines, their preparation and their use in therapy | |
| US3963660A (en) | Pyridine dioxamic acids and esters | |
| US3976780A (en) | Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide | |
| US5114954A (en) | Antiinflammatory benzylselenobenzamides from aminopyridines and picolylamines | |
| US3329569A (en) | Hypotensive compositions and methods of producing hypotension | |
| US3538106A (en) | 2-(trihalogenoanilino)-nicotinuric acid,the corresponding glycinates and derivatives thereof | |
| JPS6028978A (ja) | １，８−ナフチリジン誘導体 | |
| US5179089A (en) | Isoquinoline compounds, compositions and use | |
| US3935229A (en) | Esters of 2-[(4-quinolyl)amino]-benzoic acids | |
| JPS62148490A (ja) | １−Ｈ−ピリド−〔３，２−ｂ〕〔１，４〕−チアジン | |
| US3941775A (en) | 6-Aza-3H-1,4-benzodiazepines | |
| US4038398A (en) | Compounds, compositions and methods of use |